Journal
AMERICAN JOURNAL OF HUMAN GENETICS
Volume 100, Issue 2, Pages 238-256Publisher
CELL PRESS
DOI: 10.1016/j.ajhg.2017.01.011
Keywords
-
Categories
Funding
- Wellcome Trust Senior Investigator Award [WT098424AIA]
- MRC Programme [MR/J0003042/1, MR/L020149/1]
- Biotechnology and Biological Sciences Research Council [BB/J015873/1]
- Diabetes UK [BDA/11/0004210, BDA/15/0005275]
- Imperial Confidence in Concept (ICiC) grants
- Royal Society Wolfson Research Merit Award
- Societe Francophone du Diabete
- MRC Experimental Challenge grant [MR/L020149/1]
- Innovative Medicines Initiative Joint Undertaking [155005]
- European Union's Seventh Framework Programme (FP7)
- European Federation of Pharmaceutical Industries and Associations (EFPIA) companies
- Wellcome Trust [090532, 098381, 106130]
- NIH (US) [U01-DK105535, R01-MH101814]
- Oxford NIHR Biomedical Research Centre
- Novo Nordisk postdoctoral fellowship
- Alberta Diabetes Foundation
- University of Alberta
- Killam Annual Professorship [20162017]
- NIH [P30-DK063491]
- University of Oxford
- MRC [MR/K001981/1, MR/L020149/1] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BB/J015873/1] Funding Source: researchfish
- Medical Research Council [MR/L020149/1, MR/K001981/1] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0611-10099] Funding Source: researchfish
Ask authors/readers for more resources
Genetic variants near ARAP1 (CENTD2) and STARD10 influence type 2 diabetes (T2D) risk. The risk alleles impair glucose-induced insulin secretion and, paradoxically but characteristically, are associated with decreased proinsulin:insulin ratios, indicating improved proinsulin conversion. Neither the identity of the causal variants nor the gene(s) through which risk is conferred have been firmly established. Whereas ARAP1 encodes a GTPase activating protein, STARD10 is a member of the steroidogenic acute regulatory protein (StAR)-related lipid transfer protein family. By integrating genetic fine-mapping and epigenomic annotation data and performing promoter-reporter and chromatin conformational capture (3C) studies in 3 cell lines, we localize the causal variant(s) at this locus to a 5 kb region that overlaps a stretch-enhancer active in islets. This region contains several highly correlated T2D-risk variants, including the rs140130268 indel. Expression QTL analysis of islet transcriptomes from three independent subject groups demonstrated that T2D-risk allele carriers displayed reduced levels of STARD10 mRNA, with no concomitant change in ARAP1 mRNA levels. Correspondingly, beta-cell-selective deletion of StarD10 in mice led to impaired glucose-stimulated Ca2+-dynamics and insulin secretion and recapitulated the pattern of improved proinsulin processing observed at the human GWAS signal. Conversely, overexpression of StarD10 in the adult beta cell improved glucose tolerance in high fat-fed animals. In contrast, manipulation of Arap1 in 13 cells had no impact on insulin secretion or proinsulin conversion in mice. This convergence of human and murine data provides compelling evidence that the T2D risk associated with variation at this locus is mediated through reduction in STARD10 expression in the 13 cell.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available